Myovant Sciences Ltd.
Myovant Sciences Ltd. (MYOV): 43 pipeline candidates · ~8 mo cash runway · 15 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.9 months
D/E -1.72 · 0% dilution
Lead: Phase 3
43 candidates
N/A
N/A
A transparent, data-derived signal for Myovant Sciences Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$256.8M
Quarterly Burn
$117.9M
Runway
7.9 mo
Revenue
$100.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (43 candidates)
| Drug | Phase |
|---|---|
| Abiraterone Acetate | Phase 2 |
| Androgen-deprivation Therapy | Phase 3 |
| Antiandrogen Therapy | Phase 2 |
| Apalutamide | Phase 3 |
| ARX517 | Phase 1 |
| Bicalutamide | Phase 3 |
| Cabazitaxel | Phase 1 |
| Cetrelimab | Phase 1 |
| Darolutamide | Phase 4 |
| Darolutamide Oral Tablet | Phase 4 |
Showing 10 of 43 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Myovant Sciences Ltd.'s pipeline?
Myovant Sciences Ltd. (MYOV) has 43 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Myovant Sciences Ltd.'s lead drug candidate?
Myovant Sciences Ltd.'s most advanced tracked candidate is Abiraterone Acetate (Phase 2) for Adult Ovarian Granulosa Cell Tumor; Breast Cancer.
What is Myovant Sciences Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Myovant Sciences Ltd. has approximately 7.9 months of cash runway.
Who is the CEO of Myovant Sciences Ltd.?
Chief Executive Officer is the chief executive officer of Myovant Sciences Ltd. (MYOV).
Get the full picture on Myovant Sciences Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.